Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics of a
single-dose of YPEG-Filgrastim in cancer patients receiving chemotherapy, and will establish
dose-response relationships between YPEG-Filgrastim and Filgrastim(rhG-CSF, TOPNEUTER).
Phase:
Phase 1
Details
Lead Sponsor:
Xiamen Amoytop Biotech Co., Ltd.
Collaborator:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences